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In the UK, there are ~20 000 deaths within 30 days of
surgery every year, 9000 of which have a cardiac cause.93
The number of major cardiac complications is likely to be in
the region of 150 000 per annum. As 60% of patients who
die within 30 days of surgery suffer from coronary artery
disease94 it is reasonable to assume that the majority of
cardiac complications of anaesthesia and surgery results
from myocardial ischaemia leading to myocardial injury
(Fig. 1).
Myocardial responses to ischaemia
Acute myocardial ischaemia
The acute occlusion or progressive constriction of a
coronary artery causes reduction or abolition of systolic
shortening and thickening of the ischaemic wall.81
Ischaemic segments also demonstrate paradoxical wall
motion (termed post-systolic shortening or post-systolic
thickening). These functional changes relate directly to the
severity of the reduction in coronary blood ¯ow. As post-
systolic shortening and thickening occur after aortic valve
closure, they do not contribute to ejection and result in an
internal shift of blood in the ventricle, and may impair
relaxation. Acute or progressive ischaemia of the left
ventricle also cause an increase in chamber stiffness in the
ischaemic and in remote non-ischaemic segments.81 This
generalized increase in myocardial chamber stiffness con-
tributes to an elevation of the left ventricular end-diastolic
pressure, especially in the presence of volume loading.81
The increase in end-diastolic pressure contributes to a
vicious circle as it further impairs coronary blood ¯ow by
increasing diastolic wall tension. The mechanisms of the
increase in ventricular chamber stiffness of remote, well-
perfused myocardium have not been elucidated. However,
ventricular stiffening does not depend on loading conditions
and is likely to result from the release of mediators.
Mechanisms of myocardial ischaemia
The time-course of the effects of ischaemia on cardiac tissue
is well known. There is a marked reduction of contractile
function resulting from decreased ATP production a few
seconds after the onset of ischaemia. Leakage of potassium
ions is responsible for the alterations of ST-segments.
Within minutes, an intracellular acidosis develops associ-
ated with an increase in myoplasmic Ca2+ and the beginning
of cell swelling. Later, cellular lesions become irreversible.
The ultrastructure of the cells becomes altered and
macromolecules (CK-MB, troponins) are released. An
increased concentration of cytosolic and mitochondrial
Ca2+ plays a central role in the damage to the cells and their
membranes104 (Fig. 2).
Myocardial ischaemia occurs in the presence of ®xed or
dynamic coronary artery stenoses and, in the case of the
right ventricle, in response to afterload mismatch. The main
causes of ischaemia with ®xed coronary stenoses include
tachycardia, excessive left ventricular ®lling, and hypox-
aemia. Tachycardia, systolic hypertension and b-adrenergic
stimulation increase the oxygen requirements and may
decrease oxygen delivery. Causes of ischaemia in the
presence of dynamic stenoses include those described above
and, in addition, activation of sympathetic and parasympa-
thetic systems. Moreover, several endothelium-derived
mediators may enhance vasoconstriction.
In the normal heart, the role of the autonomic nervous
system is overshadowed by local metabolic coronary
vasoregulation. Normally, activation of the sympathetic
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nervous system at the level of a1- and b1-adrenoceptors
increases blood pressure, heart rate, and contractility. As a
result, myocardial oxygen consumption increases and local
vasoregulation decreases coronary vascular resistance. The
direct effect of a1-adrenoceptor stimulation, vasoconstric-
tion, is minimal under normal circumstances but may be
exaggerated in the presence of coronary artery disease,
extreme exercise, or haemorrhagic shock. Activation of the
parasympathetic system causes bradycardia and hypoten-
sion, thereby reducing myocardial oxygen requirements.
Local regulation increases coronary vascular resistance and
the direct coronary vasodilatation caused by acetylcholine is
masked.
Endothelins act on vascular smooth muscle and are
extremely powerful vasoconstrictors. However, they exert
complex physiological effects. Through activation of
endothelin B (ETB)-receptors, endothelial nitric oxide
synthase is activated and nitric oxide is released causing
cGMP-mediated vasodilatation. Activation of ETB-recep-
tors also increases the activity of cyclo-oxygenase leading to
the release of prostaglandin I2 (PGI2). The latter causes
vasodilatation and minimizes smooth muscle cell prolifer-
ation. When the endothelium is normal, there is a delicate
balance between vasoconstriction and vasodilatation in
response to endothelins. The vasodilatory role of the
endothelium becomes more apparent when it is damaged
by atheroma, hypercholersterolaemia, hypertensive heart
disease, and after reperfusion. An imbalance of mediators
can then develop and facilitate vasoconstriction. There are
several important mechanisms involved in this vasocon-
striction. Norepinephrine causes a1-adrenoceptor-mediated
Fig 2 Changes and consequences of cation ¯uxes during ischaemia-
reperfusion. (A) Cessation of oxygen supply in ischaemia leads to a loss
of ATP production and an increase of reactive oxygen species (ROS) in
the mitochondria. Reduced activity of the ATP consuming Na+-K+-pump
lowers the outside±inside sodium gradient, Na+ accumulates in the
myocyte and the resting membrane potential is lowered. With the
development of acidosis, the Na+-H+-exchanger (NHX) further increases
intracellular Na+. Under these conditions the Na+-Ca2+-exchanger (NCX)
operates in the reverse mode, letting Ca2+ into the cell. Ca2+ also enters
through the sarcolemmal L-type voltage-gated Ca2+-channel (L) as the
resting membrane potential is low. The increased Ca2+ is taken up into
the sarcoplasmic reticulum (SR) by the SR Ca2+-pump SERCA2 (P) and
released from there via two types of release channels, the ryanodine
receptor channel (RYR) and the IP3 receptor channel (IP3R), leading to
contraction. (B) Reoxygenation during reperfusion restores ATP
production with a further boost of ROS. Reactivation of the Na+-K+-
pump by ATP slowly restores the sodium gradient leading to normal
cation ¯uxes with the NCX eventually extruding the excess of cytosolic
Ca2+. During the early reperfusion phase when the intracellular Ca2+
level is still high, myocardial contracture (supercontraction of myocytes)
may develop. When contracture affects the entire heart as it may occur
after global ischaemia, it has been termed the `stone heart'
phenomenon.104 157
Fig 1 Schematic characterization of cardiac `stunning' and `hibernation'.
In stunning normal blood ¯ow and energy metabolism are accompanied
by reduced contractility, designated as `¯ow-contractility mismatch'. The
impaired contractile function seems to be caused primarily by increased
intracellular Ca2+, activation of Ca2+-dependent non-lysosomal cysteine
proteinases (calpains), and degradation of sarcomere-associated proteins
including troponin-I. Hibernation is characterized by reduced contractility
accompanied by reduced oxygen consumption as a consequence of
reduced blood ¯ow. Partially damaged cardiomyocytes can be rescued to
full function after stunning as well as after hibernation, provided normal
blood ¯ow is restored after the latter within the critical time period
before irreversible cell damage has occurred. Despite their distinct
de®nition, stunning and hibernation may merely represent intermediary
states in a continuum extending from unimpaired functional myocytes to
necrosis.157
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vasoconstriction. When the endothelium is damaged,
acetylcholine causes muscarinic receptor mediated vaso-
constriction,79 instead of endothelium-dependent vaso-
dilatation. Thus, with endothelial damage both
sympathetic and parasympathetic stimulation may cause
coronary vasoconstriction. As sympathetic overactivity is
part of the perioperative stress response, exaggerated
vasoconstriction may be expected to contribute to peri-
operative myocardial ischaemia and cardiac damage.
Similarly, the effects of endothelins are altered when the
endothelium is damaged and activation of nitric oxide-
synthase and cyclo-oxygenase does not occur.
Consequently, only effects of endothelins in these circum-
stances are those on endothelin A (ETA)- and ETB-receptors
in vascular smooth muscle resulting in vasoconstriction and
smooth muscle proliferation.
Myocardial stunning (¯ow-contractility mismatch)
The term myocardial stunning was coined by Braunwald
and Kloner14 in 1982 to describe a reduction in function
after a brief period of ischaemia followed by reperfusion.
The impairment of function could last for several hours or
days at a time when coronary blood ¯ow was normal and
there was no obvious cellular damage. In clinical practice,
interventions such as transluminal coronary angioplasty,
coronary artery bypass graft surgery, and thrombolysis after
myocardial infarction are human models of ischaemia-
reperfusion phenomena. During the perioperative period, a
high proportion of adult patients suffer from episodes of
myocardial ischaemia, most of which are silent but can be
prolonged. Importantly, silent myocardial ischaemia is
supposed to be a common cause of myocardial stunning
and is a predictor of adverse cardiac outcome.
Mechanisms of myocardial stunning
Myocardial ischaemia followed by reperfusion causes
reversible or irreversible damage depending on its duration
(Figures 1 and 2). In stunning, ischaemic damage is, in
principle, reversible.67 Three main mechanisms are in-
volved in the establishment of stunned myocardium:
formation of free oxygen radicals, accumulation of intra-
cellular Ca2+, and degradation of contractile proteins. Many
studies have shown that during ischaemia, but more
importantly during reperfusion, considerable production of
free oxygen radicals occurs.99 Free radicals do not have a
single target, but adversely affect many components of the
cell including sarcolemmal and subcellular membranes of
organelles. The role of free radicals in stunning is con®rmed
by the improved post-ischaemic functional recovery in the
presence of superoxide dismutase.138 Production of free
radicals involves xanthine oxidase, oxidation of catechol-
amines, uncoupling of mitochondrial respiration, and
activation of neutrophils.
During ischaemia and the early phase of reperfusion,
there is an increase in the concentration of intracellular
Ca2+. Although disappearing in the late phase of
reperfusion, Ca2+ overload can decrease the sensitivity of
contractile proteins to Ca2+, thus diminishing the
developed force.9 Ca2+ overload my result from altered
characteristics of the Na+/Ca2+ antiport and from altered
Ca2+ ¯uxes at the level of the sarcoplasmic reticulum. Such
alterations in Ca2+ handling may be attributable to
ischaemia-induced intracellular acidosis. During the early
phase of reperfusion, the H+/Na+ antiport is maximally
stimulated. While the acidosis is progressively corrected,
there is an increase in intracellular Na+ leading to a further
increase in Ca2+.
Furthermore there is some evidence that translocation of
heat-shock proteins (Hsp-27, aB-crystalline) with covalent
binding to myo®brils, together with degradation of con-
tractile proteins such as troponin I, as evidenced in a
transgenic mouse model overexpressing troponin I frag-
ments,88 may be, at least in part, involved in the
pathogenesis of myocardial stunning. Also, an increase in
coronary vascular resistance and a reduction in vasodilator
response were previously reported during reperfusion and
may represent some sort of vascular counterparts of
stunning in endothelial cells (`microvascular stunning').10
However, not all studies con®rm this phenomenon.32
Myocardial hibernation
The concept of myocardial hibernation was put forward by
Rahimtoola in 1985.110 111 In the hibernating myocardium,
ventricular function is diminished as a consequence of
insuf®cient coronary blood ¯ow (Fig. 1). However, this
reduction is not necessarily permanent: an improved
balance of supply and demand may augment myocardial
function.7 78 The issue of myocardial hibernation is clinic-
ally important because the risk of adverse cardiac outcome
in cardiac and non-cardiac surgery increases with a
reduction of the ejection fraction. If coronary revasculariza-
tion increases the ejection fraction the risk of adverse
cardiac outcome is likely to be reduced. The likelihood of
improved function after coronary reperfusion can be
predicted by the result of a dobutamine stress echocardio-
gram. If dobutamine worsens ventricular function (revers-
ible ischaemia) coronary revascularization is likely to
improve cardiac function.1
Mechanisms of myocardial hibernation
In hibernating myocardium, cardiac metabolism is down-
regulated. It has been proposed that abolition of contractility
of hibernating cardiac tissue is attributable to chronic
stunning caused by multiple episodes of severe ischaemia
followed by repetitive reperfusion. Other experimental
models suggest that hibernation occurs as a result of chronic
low-¯ow states. In either case, hibernating myocardium
should be salvageable by restitution of an adequate coronary
blood ¯ow.
Myocardial injury in perioperative medicine
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Myocardial preconditioning
In 1986, Reimer and colleagues112 reported that a brief
period of ischaemia decreased the rate of ATP depletion
during a further period of ischaemia. Murry and col-
leagues89 reported that brief periods of ischaemia made the
heart more resistant to infarction during a subsequent acute
coronary occlusion, reducing the infarct size by 70±80%.
This phenomenon, termed myocardial preconditioning is
the most powerful means of achieving cardiac protection.
Protection conferred by ischaemic and (most) pharmaco-
logical preconditioning protocols exhibits two windows: an
acute memory phase that develops within minutes of the
ischaemic stimulus and lasts only between 1 and 3 h (classic
or early preconditioning), and a longer, more delayed, phase
(late preconditioning) starting after 12±24 h and persisting
for 2±4 days.156 Delayed protection by preconditioning is
thought to be primarily attributable to alterations in gene
expression. Myocardial preconditioning has been docu-
mented in all animal species in which it has been studied and
in human cardiac tissue. Whether preconditioning facilitates
the recovery of function in stunned myocardium is still
debated.19 101 However, delayed preconditioning, in con-
trast to early preconditioning, always confers protection
against stunning.
Preconditioning can result from successive episodes of
angina or silent myocardial ischaemia. Indeed, infarct size is
known to be smaller, if it has been preceded by
angina.69 91 100 Preconditioning also reduces the risk of
ischaemia-induced ventricular tachycardia and ventricular
®brillation.145 In an almost experimental situation, pre-
conditioning can occur during coronary angioplasty where
several temporary occlusions are applied and the effects of a
longer period of occlusion are minimized. During coronary
angioplasty, sequential occlusions cause less angina,
smaller ST-segment changes and lesser lactate production
than the ®rst 90 second occlusion.28 Also, delayed
preconditioning can be observed after prolonged nitro-
glycerin administration in patients undergoing angioplasty
24 h later. Although ischaemic preconditioning, or agents
that mimic preconditioning, elicit cardiac protection in
patients undergoing cardiac surgery,51 the clinical use of
preconditioning in cardiac surgery is controversial as some
studies show bene®ts48 148 while others do not,59 72 102 or
even demonstrate deleterious effects.
Mechanisms of myocardial preconditioning
Ischaemic stimuli cause the release of stress mediators such
as adenosine, bradykinin, norepinephrine, and opioids. The
mechanisms of preconditioning involve several types of
triggers and mediators156 (Fig. 3). Amongst them, adenosine
A1- and A3-receptors, bradykinin2-receptors, d1-opioid
receptors and a1-adrenoceptors play an important role.
Via G-proteins, phospholipase C (PLC) and protein kinase
C (PKC), these receptors act on mitochondrial and
sarcolemmal KATP channels and Ca
2+ channels.152 153 As
many mediators are involved in preconditioning, and many
substances are capable of preventing it, a `summation
hypothesis' has been proposed by Downey and col-
leagues.31 36 In order for ischaemic preconditioning or
pharmacological preconditioning to occur, it is necessary to
reach an activation threshold. This threshold represents the
sum of the activity of several mediators. The role of lactate
as a triggering mechanism is controversial, even though
lactate can open KATP channels and increase the expression
of heat-shock proteins.4 65 Ischaemic preconditioning is
caused by temporary occlusions, generally lasting 5 min,
followed by reperfusion. A comparison of various numbers
of cycles of ischaemia-reperfusion shows that protection is
best with 1±4 cycles. With six or more cycles protection is
reduced und ultimately lost.47 While one cycle may be
enough to trigger the release of protective substances, many
more cycles may be unable to enhance further release of
triggers. A high number of short ischaemic periods may start
to cause cumulative ischaemic damage, thus decreasing the
ef®cacy of preconditioning.47
Preconditioning reduces cardiomyocyte necrosis in vivo
and in vitro. Apoptosis is known to increase with ischaemia.
Fig 3 Main signalling pathways in ischaemic preconditioning.
Stimulation of G-protein coupled receptors by primary messengers
activates phospholipases (PL), which in turn produce two second
messengers originating from phosphatidylinositol bisphosphate (PIP2),
namely inositol trisphosphate (IP3) and diacylglycerol (DAG). The
former releases Ca2+ from the sarcoplasmic reticulum (SR) via the IP3
receptor channel (IP3R), the latter activates different PKC isoforms
(PKC). PKC isoforms translocate to their appropriate target sites,
activating the sarcolemmal and mitochondrial ATP-dependent potassium
channels (K) and initiating distinct gene expression in the cell nucleus.
Nitric oxide originating from either the endogenous NO-synthase (NOS)
or from extracellular sources may also activate PKC and the potassium
channels directly or via its reactive nitrogen oxide products (not shown
in this ®gure). The same mechanism holds true for the reactive oxygen
species (ROS) that are produced in the mitochondria under stress and
increased Ca2+. Ca2+ enters the myocyte via the L-type voltage-gated
Ca2+-channel (L) and is taken up into the SR by the Ca2+-pump
(SERCA2). Ca2+-release from the SR for contraction primarily occurs via
the ryanodine receptor channel (RYR).
Zaugg et al.
24
In ischaemia-reperfusion, both ischaemia and reperfusion
contribute equally to apoptosis.76 By contrast, necrosis
occurs primarily during reoxygenation. Preconditioning
effectively reduces necrosis and apoptosis. Opening of
KATP channels together with modulation of Ca
2+ homeo-
stasis may explain why inhalation anaesthetics inhibit
apoptosis in cardiomyocytes.3 151
Role of adenosine
The role of adenosine in preconditioning has been well
documented. Adenosine A1-receptor activation plays an
important role. These receptors are coupled with KATP
channels68 via Gi-proteins. Activation of adenosine recep-
tors decreases the production of reactive oxygen species and
attenuates myocardial stunning.92 The role of adenosine
receptors in preconditioning is con®rmed by the observation
that adenosine A1-receptor antagonists can block KATP
channels, thereby preventing ischaemic preconditioning. In
addition, preconditioning can be mimicked by adenosine
A1-receptor agonists.
Role of bradykinin
Bradykinin is an in¯ammatory stress mediator and a
vasodilator. In some experimental models, an infusion of
bradykinin has been shown to reduce ischaemic injury,15 36
while bradykinin receptor antagonists negated the protec-
tion conferred by ischaemic preconditioning.15 36
Role of opioids
Morphine and fentanyl have been shown to precondition
the myocardium.58 120 152 Conversely, d-opioids receptor
antagonists prevent ischaemic preconditioning.84 122 123
Role of adrenergic receptors
Both a- and b-adrenoceptors are involved in precondition-
ing. While preconditioning is induced primarily by b1-
adrenoceptors,34 b2-adrenoceptor may play a role via
activation of L-type calcium channels. Brief episodes of
ischaemia cause the release of norepinephrine in the
myocardium, while exogenous a1-adrenoceptor agonists
may cause pharmacological preconditioning.132
Role of free oxygen radicals and nitric oxide
Free radicals cause myocardial damage during ischaemia-
reperfusion. However, treatment with small amounts of free
radicals before an ischaemic insult can reduce infarct size
in vitro,6 an effect that is abolished by free radical
scavengers. Nitric oxide-cGMP signalling is also
important.25 33 92 152 Inhalation anaesthetics may modulate
the activity of various isoenzymes of nitric oxide synthase
(nNOS, eNOS, iNOS) as they are heterogeneously
distributed in the myocardium.
Calcium ions
A preischaemic increase in Ca2+ represents a second
messenger in the development of ischaemic precondition-
ing,85 even though Ca2+ overload is a major contributor to
cell damage. Short-time administration of increased Ca2+
concentrations to myocardial tissue is an effective pre-
conditioning stimulus, which can be inhibited by adminis-
tration of Ca2+ channel blockers.141
Protein kinase C (PKC)
PKC transfers g-phosphoryls from ATP to hydroxyl groups
of serine/threonine residues in proteins. This phosphoryl-
ation controls the function of many cellular effectors. PKC
plays an important role in ischaemic and pharmacological
preconditioning.50 113 134 139 PKC activators can induce,
while PKC inhibitors prevent preconditioning.150 Inhala-
tion anaesthetics may directly activate PKC. Importantly,
preconditioning-associated isoform translocation of PKC to
subcellular targets is highly dependent on species, age, and
on the type of preconditioning stimulus.
Role of ATP-dependent potassium channels (KATP channels)
Ultimately, KATP channels hold the central role in ischaemic
and pharmacological preconditioning153 (Figures 2 and 3).
Sarcolemmal KATP channels were described by Noma in
1983.96 These channels open when ATP levels fall, allowing
potassium ef¯ux so causing membrane hyperpolarization
and reducing the action potential duration. These changes
decrease the open probability of voltage-gated Ca2+ chan-
nels. The resulting reduction in Ca2+ concentration pre-
serves ATP levels and reduces coronary vascular tone.118
The increase in extracellular potassium also facilitates
coronary vasodilatation and increases blood ¯ow to the
ischaemic region.5 KATP channels mediate the response to
hypoxia and the hyperaemic response to brief coronary
occlusions. However, reduction of action potential duration
does not correlate with the reduction in infarct size. Surface
KATP channels were initially thought to mediate precondi-
tioning. More recent evidence indicates that mitochondrial
KATP channels play a pivotal role in mediating cardiac
preconditioning.35 153 Opening of mitochondrial KATP
channels may optimize mitochondrial energy production,
decrease mitochondrial Ca2+ overload, and prevent
opening of mitochondrial permeability transition pores
(Fig. 4).30 43 83 157 Numerous studies have con®rmed the
important role of these channels. The role of KATP channels
in human preconditioning is evidenced by the observation
that ischaemic preconditioning does not occur in patients
taking sulfonylureas, as these agents block KATP
channels.13 21
Other bene®cial effects associated with cardiac
preconditioning
Glycogen depletion and lactate accumulation during
ischaemic preconditioning periods play a role in myocardial
protection. Indeed, transient exposure to lactate improves
contractile recovery in rat heart.29 Entrapment of neutro-
phils and platelets in the coronary vasculature occurs in
ischaemia. The protective effects of preconditioning also
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extend to the endothelium of the coronary vasculature and to
the adhesion properties of platelets and leucocytes to these
vessels. Ischaemic preconditioning reduces ICAM-1 pro-
duction and thus neutrophil entrapment.116 In turn, reduced
neutrophil and platelet entrapment is associated with
enhanced post-ischaemic function.44 45
Late preconditioning
Late preconditioning is mediated by inducible nitric oxide
synthase129 146 and can be elicited by nitric oxide
donors.46 130 It can also be triggered by heat stress,
lipopolysaccharides (LPS), or monophosphoryl lipid A;
these are known to trigger delayed endogenous protective
mechanisms against myocardial ischaemia-reperfusion
injury appearing after 24 h and lasting for several days.11
Alterations of gene expression of protective and anti-
protective proteins along with KATP channel opening have
been proposed as the main mechanisms for this delayed
protection. The endocannabinoid system is involved in the
protection conferred by LPS, in relation with nitric oxide
production.74 Two endocannabinoids act through inter-
action with G-protein coupled membrane receptors, namely
CB1- and CB2-receptors, which are present throughout the
body.103 Endocannabinoids have been implicated in the
in¯ammatory response. In isolated rat hearts, endocannabi-
noids acting through CB2-receptors and nitric oxide, play a
role in the protection conferred by heat stress against
myocardial ischaemia.52 Hemin is an activator of the potent
antioxidant enzyme heme oxygenase-1 and may play a role
in delayed protection.149 Enhanced expression of heme
oxygenase-1 has been observed during the recovery phase
of porcine myocardial stunning.125 Indeed, in experimental
studies, a signi®cant attenuation of stunning, as evidenced
by enhanced recovery of wall thickening was observed in
animals pretreated for 1 week with hemin.143 Whether
inhalation anaesthetics are capable of elicting late pre-
conditioning is not yet clear.
Remote preconditioning
Ischaemic preconditioning can be generated by short
episodes of myocardial, limb, or visceral ischaemia. In the
heart itself, preconditioning can develop in areas remote
from the preconditioning ischaemic stimulus (for review
see156). This remote preconditioning may involve the
release of adenosine, bradykinin, norepinephrine, and
activation of KATP channels. Systemic effects of localized
ischaemic preconditioning have been reported. This raises
the issue that regional ischaemia of non-vital tissues might
protect remote vital organs.37 In volunteers, transient remote
ischaemia of one limb induced remote ischaemic precondi-
tioning of the opposite limb as evidenced by preservation of
endothelial function (estimated as extent of vasodilator
response).66 Cytokines and other metabolic mediators are
likely to play a role. The autonomic system may also be
involved as well as modulation of platelet, endothelium, and
leucocyte function.
Protective effects of anaesthetics against
ischaemia
Anaesthetics and myocardial stunning
Most inhalation anaesthetics and high dose opioids confer
protection, increasing the rate of myocardial recovery after
reperfusion.58 115 In 1988, Warltier and colleagues142
demonstrated that administration of halothane and iso¯ur-
ane before ischaemia improved the speed of recovery of
function after a brief (15 min) period of ischaemia. After 5 h,
the functional recovery in the presence of inhalation
anaesthesia was 100% vs 50% only in the controls.142
Since then, these observations have been con®rmed repeat-
edly.22 134 However, some studies of isolated heart prepar-
ations showed no protection by inhalation anaesthetics.97 117
More recently, sevo¯urane and des¯urane were shown to
confer cardiac protection.108 109 119 133 135 It is likely that
protection by inhalation anaesthetics is attributable to
pharmacological preconditioning of the heart, as in many
studies the inhalational anaesthetic was given before
ischaemia and reperfusion. Indeed, in some studies the
administration of the inhalation anaesthetic was discon-
tinued before ischaemia-reperfusion and resulted in reduced
infarct size.18 24 Nonetheless, protective effects of inhal-
ation anesthetics were also reported if inhalation anaes-
thetics were administered exclusively during the reperfusion
phase.
Intravenous anaesthetics appear to confer less protec-
tion.23 27 144 Fentanyl and propofol appear to be equiva-
lent.114 In the isolated heart, as opposed to the intact
instrumented heart, propofol has been shown to reduce
infarct size and cellular damage.70 71 82 Propofol-induced
protection was not abolished by block of KATP channels.
While the effects of opioids on infarct size have been well
demonstrated, there are only a few studies of their effects on
myocardial stunning.114 144 In the isolated heart, high
concentrations of fentanyl have been shown to offer
signi®cant protection.58 Protection was mediated by
d-opioid receptors, adenosine A1-receptors, PKC, and
KATP channels.
56 57 The role of d-opioid receptors is
supported by the abolition of their protective effect by
naloxone.20 122 131 As wash-out of opioids does not prevent
their effect, they must act as preconditioning agents.2 75 It is
further possible that opioids act bene®cially via a reduction
in adhesion and migration of neutrophils.128 140
Anaesthetics and cardiac preconditioning
Many anaesthetic agents have been shown to reduce infarct
size in experimental models. Not all anaesthetics have the
same ef®cacy. There is greater reduction of infarct size by
halothane, en¯urane, and iso¯urane in comparison with
pentobarbital, ketamine-xylazine, or propofol anaesthesia in
rabbits. Dogs anaesthetized with barbiturates exhibit larger
infarcts than their conscious counterparts.53 This may be
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explained by the observation that barbiturates competitively
antagonize adenosine A1-receptors, a pivotal signalling
pathway in cardiac preconditioning. Indeed, adenosine
receptor antagonists decrease anaesthesia-induced precon-
ditioning.24 113 The same is true of PKC antagonists.134
Albeit not proven, it may be speculated that pharmaco-
logical preconditioning by inhalation anaesthetics may be of
smaller magnitude than ischaemic preconditioning.18
Pharmacological preconditioning by inhalation anaes-
thetics appears to be primarily mediated by stimulation of
adenosine receptors113 and activation of KATP chan-
nels.62 113 Protective effects by inhalation anaesthetics also
occur in the presence of cardioplegic protection. Ischaemic
and anaesthetic-induced preconditioning are not additive
suggesting the same end-effector,12 identi®ed in many
studies as KATP channels. Nonetheless, sevo¯urane can
potentiate late ischaemic preconditioning in an in vivo rabbit
model.87 The signalling components involved in cardiac
protection by inhalational anaesthetics, are similar to
ischaemic preconditioning, but show distinct differences.26
Both sarcolemmal and mitochondrial KATP channels may
mediate anaesthesia-induced preconditioning as demon-
strated in des¯urane-mediated preconditioning.135 Yet,
mitochondrial KATP channels may play the more important
role. Halothane partially blocks sarcolemmal KATP chan-
nels,113 while iso¯urane does not. Anaesthesia-induced
preconditioning is clearly species dependent. Halothane
preconditions in rabbit but not rat or human. Iso¯urane
preconditions in rabbit and human, but not rat (for review
see155 156).
Anaesthetics may also modulate the effects of ischaemic
preconditioning. Several anaesthetic agents have direct
effects on KATP channels (barbiturates) or have prominent
physiological effects that are induced by KATP channels
(iso¯urane, halothane).17 Accordingly, ischaemic precondi-
tioning is abolished by glibenclamide under ketamine-
xylazine anaesthesia but not pentobarbital anaesthesia. In a
comparison of the effects of ischaemic preconditioning
under pentobarbital, iso¯urane, and ketamine-xylazine
anaesthesia, infarct size was not different in the absence
of preconditioning, but the magnitude of infarct size
limitation by ischaemic preconditioning was different
depending upon the basal anaesthesia.38 In the presence of
halothane anaesthesia, nicorandil given before ischaemia
did not demonstrate protective effects, whereas ischaemic
preconditioning did reduce infarct size. Yet, a KATP channel
blocker prevented the combined effect of ischaemia and
nicorandil.90 The complexity of modulatory effects of
anaesthetics on cardiac preconditioning has been substan-
tiated in a cellular model of simulated ischaemia.
Modulatory effects of anaesthetics were demonstrated by
the inhibition of diazoxide-induced mitochondrial KATP
channel opening by R-ketamine, thiopental and pentobarbi-
tal. Conversely, urethane, 2,2,2-trichloroethanol (a main
metabolite of a-chloralose) and fentanyl potentiated the
channel-opening effect of diazoxide. This potentiation
could be blocked by chelerythrine, a speci®c PKC inhibitor.
By contrast, S-ketamine, propofol, xylazine, midazolam
and etomidate do not affect mitochondrial KATP channel
Fig 4 Functional connections between the mitochondrial permeability
transition pore (mPTP) and the oxidative energy production during
ischaemia-reperfusion and pharmacological preconditioning (PC). The
selective adenine nucleotide translocator (ANT) at the inner
mitochondrial membrane (IMM) regulates ATP supply to the cytoplasm
in exchange for ADP, which will be regenerated to ATP in the
mitochondrial matrix (MM) by the ATP synthase (ADP + Pi). The
synthase is driven by the proton gradient across the IMM. The high
proton concentration in the intermembrane space (MIMS) is maintained
by the respiratory chain complexes (I±IV), which are energetically fuelled
by the tricarboxylic acid cycle (TCAC) in the MM. On its way out of the
MM, ATP passes through the ANT and enters a channel formed by an
octameric complex of the mitochondrial creatine kinase (CK) where its
gamma-phosphoryl is transferred to creatine (Cr) to produce creatine
phosphate (CrP), which leaves the mitochondrion through the voltage-
dependent anion channel (VDAC or porin) in the outer membrane
(OMM) into the cytoplasm. Wherever energy is required,
transphosphorylation from CrP to local ADP yields ATP for immediate
use. The Cr±CK system serves as energy shuttle between the production
centre and the place of consumption. The VDAC allows solutes to pass
up to a molecular weight of 5000 Da. The nucleotide conductivity of
ANT is controlled by cyclophilin-D (CP) at its inner opening. Binding of
Ca2+ (which is increased during ischaemia-reperfusion) to CP induces
ANT to form a non-selective channel for solutes up to a molecular weight
of 1500 Da. Cyclosporin-A can bind to CP and prevents channel opening,
while atractyloside binds to ANT itself and favours channel opening.
During ischaemia cessation of ATP production produces a decrease of
diffuse K+ in¯ux. Consequently, the MM shrinks somewhat at the
expense of an increase of the MIMS leading to destabilization of the
complex between ANT, CK and VDAC. On reperfusion additional ROS
and Ca2+ trigger opening of the ANT channel, which then seems to join
directly to the VDAC forming a non-selective mega-pore, the mPTP. This
leads to the collapse of the IMM potential, to massive MM swelling and
disruption of the OMM. As K+ acts as the main MM volume regulator,
activation of K+ in¯ux represents the most powerful mechanism to
prevent mitochondrial destabilization and therewith irreversible
destruction and cell death. Both ischaemic and pharmacological PC
activate the mitochondrial ATP-dependent potassium channels (mK-ATP)
affording myocyte protection against ischaemia-reperfusion injury. In
addition, a large conductance Ca2+-activated potassium channel (K-Ca)
known to exist in the surface membrane of vascular smooth muscle cells
was also found in the MIM. This channel is regulated by physiological
variations of cytosolic Ca2+, and when selectively activated, it also
protects the myocytes against ischaemia-reperfusion injury.30 43 83 157
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activity.152 These observations illustrate the complex inter-
ference of anaesthetics with ischaemic preconditioning and
stress the concept of anaesthetics acting as modulators of
cardiac preconditioning.
To date, there are few data on the possibility of inhalation
anaesthetics conferring late preconditioning, whereas
delayed protection by opioids is well established.121 Kehl
and colleagues60 examined the effect of iso¯urane adminis-
tration 24 h before a 60 min coronary occlusion followed by
3 h reperfusion in a canine model. While iso¯urane exerted
early protection, there was no late protection. By contrast,
delayed preconditioning was observed in a rabbit model.137
Finally, improved collateral blood ¯ow may also play a
role in the bene®cial effects elicited by anaesthetics. Indeed,
sevo¯urane increases collateral ¯ow, an effect not reversed
by glibenclamide.64 In addition, halothane, iso¯urane, and
sevo¯urane reduce the number of neutrophils45 73 and
platelets44 sequestered in the coronary vasculature after
ischaemia. This may contribute to the observed bene®cial
effects. Inhalation anaesthetics further suppress the post-
ischaemic expression of CD11b45 and thus decrease
neutrophil adhesion to the endothelium.86 However, sevo-
¯urane does not reduce the expression of glycoprotein IIb/
IIIa, a platelet adhesion molecule involved in the platelet±
endothelium interaction.44
Iso¯urane
In the absence of ischaemia, iso¯urane causes opening of
KATP channels, an effect blocked by sulfonylureas.
61 This
results in a reduction in infarct size in experimental
animals.63 Iso¯urane also decreases infarct size in an
in vitro model of human myocardium.113 Sarcolemmal
and mitochondrial KATP channels appear to be invol-
ved.61 106 113 133 136 Iso¯urane increases the open probability
of the sarcoplasmic KATP channel for a given ATP
concentration.39 In a cellular model, iso¯urane signi®cantly
enhanced the diazoxide-mediated activation of mitochon-
drial KATP channels. This effect was completely blocked by
chelerythrine (a PKC inhibitor). Pretreatment with inhal-
ation anaesthetics potentiated the diazoxide-mediated pro-
tection against ischaemia. Cardioprotection was unaffected
by the sarcoplasmic KATP channel blocker HMR-1098, but
sensitive to modulation of nitric oxide and adenosine-Gi
signalling pathways.153 Administration of iso¯urane before
aortic cross-clamping in patients undergoing coronary
artery bypass surgery causes cardiac index to be higher
after cardiopulmonary bypass with less changes in ST-
segments than in the control group. However, there were no
differences in terms of arrhythmias.42 Thus, iso¯urane may
offer some additional protection to cardioplegia. These
®ndings are consistent with the observation of lower (albeit
not statistically signi®cant) perioperative levels of CK-MB
and troponin reported by Belhomme8 when iso¯urane is
used. Moreover, iso¯urane was found to increase 5¢-
nucleotidase activity in atrial tissue indicating increased
PKC activity.8
Sevo¯urane
Sevo¯urane reduces infarct size in dogs via opening of KATP
channels.133 Preservation of myocardial blood ¯ow through
collateral circulation, observed with sevo¯urane, is inde-
pendent of KATP channels. In sepsis, ultrastructural changes
in the myocardium have been documented and sevo¯urane
protected cardiac output in septic (caecal ligation and
perforation) rats.124 Recently, the ®rst clinical double-
blinded multicentre study has shown sevo¯urane to protect
myocardium and kidney in patients undergoing coronary
artery bypass grafting.54 This study also visualized for the
®rst time PKC translocation (predominantly isoforms d and
e) to subcellular targets such as the sarcolemma, mitochon-
dria, intercalated disks, and nuclei in response to sevo-
¯urane. Moreover, the observed renoprotective effect of
sevo¯urane raises the intriguing possibility that systemic-
ally administered sevo¯urane may confer multiorgan
protection in high-risk patients.
Des¯urane
In isolated human atrial trabeculae, des¯urane improved the
recovery of isometric contraction after a 30 min period of
anoxia. The preconditioning effect of des¯urane was
abolished by glibenclamide, 5-hydroxydecanoate (5-HD),
DPX (an adenosine receptor blocker), phentolamine, and
propranolol.41 These observations suggest that precondi-
tioning by des¯urane is mediated by mitochondrial KATP
channels,41 adenosine A1-receptors, and a- and b-adreno-
ceptors. In contrast, selective block of sarcolemmal KATP
channels did not reduce des¯urane-induced precondition-
ing, while it abolished anoxia-induced preconditioning.
Des¯urane increases sympathetic activity in volunteers and
releases catecholamines from myocardial stores in rat and
human myocardium.40 Preconditioning by des¯urane may
thus be, at least partly, elicited by stimulation of the a/b-
adrenoceptor pathways.77
Pharmacological interventions by
nonanaesthetic agents currently used for the
prevention of perioperative ischaemia
Several classes of drugs have been proposed in order to
reduce the risk of ischaemic complications of anaesthesia
and surgery. However, based on current clinical data, only
beta-blockers, a2-adrenoceptor agonists, and possibly
statins may have the potential to affect perioperative
cardiovascular outcome.
Nitroglycerin
While nitroglycerin is used successfully in the treatment of
myocardial ischaemia, there is no evidence that its prophy-
lactic administration before anaesthesia and surgery
decreases the risk of perioperative cardiac complications.127
Calcium channel blockers
Though effective in the management of ischaemic heart
disease, Ca2+ channel blockers have never been shown to
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offer any protection against perioperative cardiac complic-
ations of anaesthesia and surgery.126 127 This absence of
protection seems surprising in view of the strong antioxidant
effect of certain calcium channel blockers.147
Adenosine modulators
These compounds facilitate the release of the coronary
vasodilator adenosine by the ischaemic myocardium,
thereby improving collateral blood ¯ow toward the com-
promised area. Though promising results were obtained,80
development of the only agent tested in clinical trials,
acadesine, was stopped.
a2-Adrenoceptor agonists
There is renewed interest in the use of clonidine,
dexmedetomidine, and (temporarily, as it is not currently
being further developed for clinical use) mivazerol; these
drugs reduce the level of sympathetic activity and make the
circulation more stable. Clonidine decreases the risk of
perioperative myocardial ischaemia95 and a recent meta-
analysis has also shown a reduction in the risk of adverse
outcome.127 Mivazerol has been tested in a large multicentre
trial and was shown to decrease the incidence of cardiac
complications in vascular surgical patients but not in non-
vascular surgical patients,98 yet its development was
stopped.
Nicorandil
This drug is both a nitrate and a KATP channel opener. It is
effective in the management of ischaemic heart disease and
its associated dysrhythmias. It may prove useful in the
perioperative prevention of cardiac complications.55 In
clinical practice, nicorandil, a KATP channel opener and
nitrate, is widely used in the treatment of angina. Nicorandil
induces myocardial preconditioning. In isolated human
heart muscle nicorandil conferred cardioprotection (im-
proved recovery of function in a hypoxia-reoxygenation
model). This effect was abolished by ischaemic precondi-
tioning.16 In a rabbit model early treatment with nicorandil
(pre-ischaemia) decreased infarct size, while nicorandil
administration after ischaemia was ineffective. Ischaemic
preconditioning reduced infarct size and the combination of
ischaemic preconditioning and nicorandil showed ef®cacy
intermediate between ischaemic preconditioning and before
administration of nicorandil.49 The effect of nicorandil was
blocked by 5-hydroxydecanoate, a KATP channel blocker.
Thus, nicorandil appears to protect by opening KATP
channels, and to interact with ischaemic preconditioning.
By contrast, nicorandil appears to offer additional protection
when administered with iso¯urane, in terms of functional
recovery of the stunned myocardium.105
Statins
In a case-controlled study, Poldermans and colleagues107
evaluated the effects of statins on perioperative mortality in
patients undergoing major vascular surgery. In statin-treated
patients, the risk for perioperative mortality was ~20% of
that observed in non-statin-treated patients. The authors
concluded that perioperative statin use may reduce peri-
operative mortality in high-risk vascular patients.
b-Blockers
These drugs, at present, occupy centre stage for cardiac
prophylaxis because several studies have shown a reduction
in the incidence of cardiac complications of anaesthesia and
surgery in patients deliberately given beta-blockers
prophylactically.154 The bene®cial effects of perioperative
b-blocker administration are discussed in detail in another
article in this issue.
Conclusions
Myocardial ischaemic injury is a potential perioperative
threat. Ischaemia induces a palette of myocardial states with
distinct pathophysiological backgrounds ranging from the
paradoxically bene®cial effects of preconditioning on one
side to the complete loss of cellular integrity and to cell
death on the other side. Preconditioning mimicking agents
such as inhalation anaesthetics and opioids induce a
pronounced protective cardiac phenotype and thus may
decrease, along with b-blockers, a2-adrenoceptor agonists,
and anti-in¯ammatory/preconditioning-mimicking statins,
the deleterious effects of myocardial ischaemia in peri-
operative medicine.
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